{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:21:06Z","timestamp":1780600866858,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11695-026-08500-z","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:13:18Z","timestamp":1770325998000},"page":"1330-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Metabolic Bariatric Surgery: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Dorsa","family":"Shekouh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Behboodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Varmazyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khodadadiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnia","family":"Jochin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Bazrafshan drissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"8500_CR1","unstructured":"Organization WH. Cardiovascular diseases (CVDs). 2021."},{"issue":"21","key":"8500_CR2","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143(21):e984\u20131010.","journal-title":"Circulation"},{"issue":"4","key":"8500_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4239\/wjd.v5.i4.444","volume":"5","author":"I Mart\u00edn-Tim\u00f3n","year":"2014","unstructured":"Mart\u00edn-Tim\u00f3n I, et al. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444\u201370.","journal-title":"World J Diabetes"},{"issue":"1","key":"8500_CR4","first-page":"e51681","volume":"16","author":"M Pakhare","year":"2024","unstructured":"Pakhare M, Anjankar A. Critical correlation between obesity and cardiovascular diseases and recent advancements in obesity. Cureus. 2024;16(1):e51681.","journal-title":"Cureus"},{"key":"8500_CR5","doi-asserted-by":"crossref","unstructured":"Visco V et al. Interventions to address cardiovascular risk in obese patients: many hands make light work. J Cardiovasc Dev Dis, 2023. 10(8).","DOI":"10.3390\/jcdd10080327"},{"issue":"Suppl 1","key":"8500_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"9548","key":"8500_CR7","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet"},{"issue":"1","key":"8500_CR8","first-page":"9946924","volume":"2023","author":"M Wojtara","year":"2023","unstructured":"Wojtara M, et al. Glucagon-Like Peptide-1 receptor agonists for chronic weight management. Adv Med. 2023;2023(1):9946924.","journal-title":"Adv Med"},{"issue":"1","key":"8500_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"9701","key":"8500_CR10","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606\u201316.","journal-title":"Lancet"},{"issue":"11","key":"8500_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"key":"8500_CR12","doi-asserted-by":"publisher","unstructured":"Wronka M, et al. New insights into the use of liraglutide\u2014impact on cardiovascular risk and microvascular outcomes. Biomedicines. 2023;11. https:\/\/doi.org\/10.3390\/biomedicines11041159.","DOI":"10.3390\/biomedicines11041159"},{"key":"8500_CR13","doi-asserted-by":"publisher","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679.","journal-title":"Am J Prev Cardiol"},{"issue":"10193","key":"8500_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"24","key":"8500_CR15","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"8500_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"8500_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10157","key":"8500_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"6","key":"8500_CR19","first-page":"e25762","volume":"14","author":"D Chacon","year":"2022","unstructured":"Chacon D, et al. Bariatric surgery with Roux-En-Y gastric bypass or sleeve gastrectomy for treatment of obesity and comorbidities: current evidence and practice. Cureus. 2022;14(6):e25762.","journal-title":"Cureus"},{"issue":"14","key":"8500_CR20","first-page":"1726","volume":"293","author":"J.R Treadwell","year":"2005","unstructured":"Treadwell J.R. C.M. <>Turkelson 2005 Systematic review of bariatric surgery. JAMA 293 14 1726 author reply 1726.","journal-title":"JAMA"},{"key":"8500_CR21","doi-asserted-by":"publisher","first-page":"f5934","DOI":"10.1136\/bmj.f5934","volume":"347","author":"VL Gloy","year":"2013","unstructured":"Gloy VL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934.","journal-title":"BMJ"},{"issue":"7","key":"8500_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMoa1600869","volume":"376","author":"PR Schauer","year":"2017","unstructured":"Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes \u2013\u20095-year outcomes. N Engl J Med. 2017;376(7):641\u201351.","journal-title":"N Engl J Med"},{"issue":"20","key":"8500_CR23","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.107.721027","volume":"118","author":"H Ashrafian","year":"2008","unstructured":"Ashrafian H, et al. Effects of bariatric surgery on cardiovascular function. Circulation. 2008;118(20):2091\u2013102.","journal-title":"Circulation"},{"issue":"2","key":"8500_CR24","first-page":"e34723","volume":"15","author":"H Chandrakumar","year":"2023","unstructured":"Chandrakumar H, et al. The effects of bariatric surgery on cardiovascular outcomes and cardiovascular mortality: a systematic review and meta-analysis. Cureus. 2023;15(2):e34723.","journal-title":"Cureus"},{"issue":"8","key":"8500_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa066254","volume":"357","author":"L Sj\u00f6str\u00f6m","year":"2007","unstructured":"Sj\u00f6str\u00f6m L, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741\u201352.","journal-title":"N Engl J Med"},{"issue":"11","key":"8500_CR26","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.2337\/dc24-0859","volume":"47","author":"CL Axelrod","year":"2024","unstructured":"Axelrod CL, et al. Metabolomic fingerprints of medical therapy versus bariatric surgery in patients with obesity and type 2 diabetes: the STAMPEDE trial. Diabetes Care. 2024;47(11):2024\u201332.","journal-title":"Diabetes Care"},{"issue":"1","key":"8500_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2011.1914","volume":"307","author":"L Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56\u201365.","journal-title":"JAMA"},{"issue":"8","key":"8500_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa066603","volume":"357","author":"TD Adams","year":"2007","unstructured":"Adams TD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753\u201361.","journal-title":"N Engl J Med"},{"issue":"10","key":"8500_CR29","first-page":"e71684","volume":"16","author":"L Saeed","year":"2024","unstructured":"Saeed L, et al. Comparative effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists on cardiovascular outcomes and mortality: a meta-analysis. Cureus. 2024;16(10):e71684.","journal-title":"Cureus"},{"issue":"9","key":"8500_CR30","first-page":"e68390","volume":"16","author":"K Hamed","year":"2024","unstructured":"Hamed K, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus. 2024;16(9):e68390.","journal-title":"Cureus"},{"key":"8500_CR31","unstructured":"Cochrane. Cochrane handbook for systematic reviews of interventions (current version). 2024."},{"key":"8500_CR32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"10S","key":"8500_CR33","doi-asserted-by":"publisher","first-page":"S971","DOI":"10.14309\/01.ajg.0000954768.41220.8b","volume":"118","author":"AA Adekolu","year":"2023","unstructured":"Adekolu AA, et al. S1282\u2003Bariatric surgery vs glucagon-like peptide-1 analogues for reducing risk of major cardiovascular events: a multi-center retrospective cohort study. Official J Am Coll Gastroenterol | ACG. 2023;118(10S):S971.","journal-title":"Official J Am Coll Gastroenterol | ACG"},{"issue":"6","key":"8500_CR34","doi-asserted-by":"publisher","first-page":"E2415392","DOI":"10.1001\/jamanetworkopen.2024.15392","volume":"7","author":"D Dicker","year":"2024","unstructured":"Dicker D, et al. Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality. JAMA Netw Open. 2024;7(6):E2415392.","journal-title":"JAMA Netw Open"},{"key":"8500_CR35","doi-asserted-by":"crossref","unstructured":"Maan S et al. Metabolic and bariatric surgery versus glucagon-like peptide-1 receptor agonist therapy: A comparison of cardiovascular outcomes in patients with obesity. Am J Surg, 2025. 242.","DOI":"10.1016\/j.amjsurg.2025.116242"},{"issue":"4","key":"8500_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41366-023-01254-z","volume":"47","author":"E Stenberg","year":"2023","unstructured":"Stenberg E, N\u00e4slund E. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. Int J Obes. 2023;47(4):251\u20136.","journal-title":"Int J Obes"},{"key":"8500_CR37","doi-asserted-by":"crossref","unstructured":"Stenberg E et al. Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment. Br J Surg, 2024. 111(9).","DOI":"10.1093\/bjs\/znae221"},{"issue":"8","key":"8500_CR38","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/s41591-024-03052-0","volume":"30","author":"Y Wolff Sagy","year":"2024","unstructured":"Wolff Sagy Y, et al. Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure. Nat Med. 2024;30(8):2337\u201342.","journal-title":"Nat Med"},{"issue":"4","key":"8500_CR39","doi-asserted-by":"publisher","first-page":"e216820","DOI":"10.1001\/jamanetworkopen.2021.6820","volume":"4","author":"AG Doumouras","year":"2021","unstructured":"Doumouras AG, et al. Association between bariatric surgery and major adverse diabetes outcomes in patients with diabetes and obesity. JAMA Netw Open. 2021;4(4):e216820.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"8500_CR40","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jamcollsurg.2019.08.065","volume":"229","author":"S Swaminathan","year":"2019","unstructured":"Swaminathan S, Kakuturu J, Shetty S. Impact of diabetes mellitus on bariatric surgery outcomes: a metabolic and bariatric surgery accreditation and quality improvement program analysis. J Am Coll Surg. 2019;229(4):S23.","journal-title":"J Am Coll Surg"},{"issue":"6","key":"8500_CR41","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jamasurg.2025.1065","volume":"160","author":"S Wildisen","year":"2025","unstructured":"Wildisen S, et al. Major adverse cardiac events after gastric bypass vs sleeve gastrectomy. JAMA Surg. 2025;160(6):690\u2013700.","journal-title":"JAMA Surg"},{"issue":"11","key":"8500_CR42","first-page":"e73705","volume":"16","author":"S Tariq","year":"2024","unstructured":"Tariq S, et al. Long-Term cardiovascular outcomes of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes. A Syst Rev Cureus. 2024;16(11):e73705.","journal-title":"A Syst Rev Cureus"},{"issue":"20","key":"8500_CR43","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/eurheartj\/ehac071","volume":"43","author":"SL van Veldhuisen","year":"2022","unstructured":"van Veldhuisen SL, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955\u201369.","journal-title":"Eur Heart J"},{"issue":"4","key":"8500_CR44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/dc21-1113","volume":"45","author":"AK Wright","year":"2022","unstructured":"Wright AK, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 Inhibitors, GLP-1 receptor Agonists, and their combination in type 2 diabetes. Diabetes Care. 2022;45(4):909\u201318.","journal-title":"Diabetes Care"},{"issue":"4","key":"8500_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CRD.0000000000000338","volume":"29","author":"BH Mottel","year":"2021","unstructured":"Mottel BH, Lindsay DA, Frishman WH. Effect of bariatric surgery on cardiovascular function and heart failure outcomes. Cardiol Rev. 2021;29(4):187\u201394.","journal-title":"Cardiol Rev"},{"key":"8500_CR46","doi-asserted-by":"crossref","unstructured":"Kitamura RK, Morton JM, Eisenberg D. Cardiac risk factor improvement following bariatric surgery, in the ASMBS textbook of bariatric surgery, N.T. Nguyen, Editors. 2020, Springer International Publishing: Cham. pp. 519\u2013526.","DOI":"10.1007\/978-3-030-27021-6_46"},{"key":"8500_CR47","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2147\/DMSO.S389346","volume":"16","author":"G Xu","year":"2023","unstructured":"Xu G, et al. An assessment of the effect of bariatric surgery on cardiovascular disease risk in the Chinese population using multiple cardiovascular risk models. Diabetes Metab Syndr Obes. 2023;16:1029\u201342.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"8500_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.medcle.2022.07.007","volume":"159","author":"ME Arjonilla Sampedro","year":"2022","unstructured":"Arjonilla Sampedro ME, et al. Impact of ponderal loss after bariatric surgery on the cardiac structure and function. Med Cl\u00ednica (English Edition). 2022;159(3):109\u201315.","journal-title":"Med Cl\u00ednica (English Edition)"},{"issue":"9","key":"8500_CR49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl Peptidase-4 inhibitors. Circulation. 2017;136(9):849\u201370.","journal-title":"Circulation"},{"issue":"10","key":"8500_CR50","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/obr.12433","volume":"17","author":"E Zomer","year":"2016","unstructured":"Zomer E, et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev. 2016;17(10):1001\u201311.","journal-title":"Obes Rev"},{"key":"8500_CR51","doi-asserted-by":"crossref","unstructured":"SARMA S. and P. PALCU, 1433-P: comparative weight loss with GLP-1 receptor agonists vs. bariatric surgery in obesity: a systematic review and pair-wise meta-analysis. Diabetes, 2022. 71(Supplement_1).","DOI":"10.2337\/db22-1433-P"},{"issue":"3","key":"8500_CR52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/gutjnl-2022-328185","volume":"72","author":"FF Anh\u00ea","year":"2023","unstructured":"Anh\u00ea FF, et al. Human gut microbiota after bariatric surgery alters intestinal morphology and glucose absorption in mice independently of obesity. Gut. 2023;72(3):460\u201371.","journal-title":"Gut"},{"issue":"7","key":"8500_CR53","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1210\/jc.2010-2876","volume":"96","author":"Y Falk\u00e9n","year":"2011","unstructured":"Falk\u00e9n Y, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96(7):2227\u201335.","journal-title":"J Clin Endocrinol Metab"},{"key":"8500_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ajem.2024.10.050","volume":"87","author":"S Farooqi","year":"2025","unstructured":"Farooqi S, et al. High risk and low incidence diseases: bariatric surgery complications. Am J Emerg Med. 2025;87:113\u201322.","journal-title":"Am J Emerg Med"},{"key":"8500_CR55","doi-asserted-by":"crossref","unstructured":"Karimi MA et al. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Front Pharmacol, 2025. Volume 16\u20132025.","DOI":"10.3389\/fphar.2025.1438318"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08500-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-026-08500-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08500-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:03:18Z","timestamp":1774965798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-026-08500-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["8500"],"URL":"https:\/\/doi.org\/10.1007\/s11695-026-08500-z","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}